Total and isoform-specific quantitative assessment of circulating fibulin-1 using selected reaction monitoring MS and time-resolved immunofluorometry

Proteomics - Clinical Applications

Volumn 9, Issue 7-8, 2015, Pages 767-775

  Overgaard, Martin ^a,b   Cangemi, Claudia ^a   Jensen, Martin L ^a   Argraves, William S ^c   Rasmussen, Lars M ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Fibulin 1; Immunoassay; Isoform; Plasma biomarker; SRM

Indexed keywords

FIBULIN; FIBULIN 1A; FIBULIN 1B; FIBULIN 1C; FIBULIN 1D; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; ISOPROTEIN; PEPTIDE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FLUOROMETRY; HUMAN; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MOLECULAR SIZE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SIZE EXCLUSION CHROMATOGRAPHY; TIME RESOLVED IMMUNOFLUOROMETRIC ASSAY; VALIDATION PROCESS; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOASSAY; METABOLISM; MOLECULAR GENETICS; MOLECULAR WEIGHT; PROCEDURES; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; TIME;

AMINO ACID SEQUENCE; CALCIUM-BINDING PROTEINS; CHROMATOGRAPHY, GEL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PEPTIDES; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS;

EID: 84949097665     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400070     Document Type: Article

References (37)

1. Lequin, R. M., Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin. Chem. 2005, 51, 2415-2418.
2. Krastins, B., Prakash, A., Sarracino, D. A., Nedelkov, D. et al., Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46, 399-410.
3. Krisp, C., Randall, S. A., McKay, M. J., Molloy, M. P., Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. Proteomics Clin. Appl. 2012, 6, 42-59.
4. Lopez, M. F., Rezai, T., Sarracino, D. A., Prakash, A. et al., Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56, 281-290.
5. Picotti, P., Aebersold, R., Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 2012, 9, 555-566.
6. Hulsmeier, A. J., Paesold-Burda, P., Hennet, T., N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol. Cell. Proteomics 2007, 6, 2132-2138.
7. Lassman, M. E., McLaughlin, T. M., Zhou, H., Pan, Y. et al., Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2014, 28, 1101-1106.
8. Argraves, W. S., Greene, L. M., Cooley, M. A., Gallagher, W. M., Fibulins: physiological and disease perspectives. EMBO Rep. 2003, 4, 1127-1131.
9. Muriel, J. M., Dong, C., Hutter, H., Vogel, B. E., Fibulin-1C and Fibulin-1D splice variants have distinct functions and assemble in a hemicentin-dependent manner. Development 2005, 132, 4223-4234.
10. Sasaki, T., Kostka, G., Gohring, W., Wiedemann, H. et al., Structural characterization of two variants of fibulin-1 that differ in nidogen affinity. J. Mol. Biol. 1995, 245, 241-250.
11. Fujimoto, N., Terlizzi, J., Brittingham, R., Fertala, A. et al., Extracellular matrix protein 1 interacts with the domain III of fibulin-1C and 1D variants through its central tandem repeat 2. Biochem. Biophys. Res. Commun. 2005, 333, 1327-1333.
12. Debeer, P., Schoenmakers, E. F., Twal, W. O., Argraves, W. S. et al., The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly. J. Med. Genet. 2002, 39, 98-104.
13. Lau, J. Y., Oliver B. G., Baraket, M., Beckett, E. L. et al., Fibulin-1 is increased in asthma-a novel mediator of airway remodeling? PLoS One 2010, 5, e13360.
14. Bardin, A., Moll, F., Margueron, R., Delfour, C. et al., Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 2005, 146, 760-768.
15. Moll, F., Katsaros, D., Lazennec, G., Hellio, N. et al., Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 2002, 21, 1097-1107.
16. de, V. S., Iwamoto, T., Yamada, Y., Fibulins: multiple roles in matrix structures and tissue functions. Cell. Mol. Life Sci. 2009, 66, 1890-1902.
17. Cangemi, C., Skov, V., Poulsen, M. K., Funder, J. et al., Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin. Chem. 2011, 57, 1556-1565.
18. Balbona, K., Tran, H., Godyna, S., Ingham, K. C. et al., Fibulin binds to itself and to the carboxyl-terminal heparin-binding region of fibronectin. J. Biol. Chem. 1992, 267, 20120-20125.
19. Tran, H., VanDusen, W. J., Argraves, W. S., The self-association and fibronectin-binding sites of fibulin-1 map to calcium-binding epidermal growth factor-like domains. J. Biol. Chem. 1997, 272, 22600-22606.
20. Argraves, W. S., Tran, H., Burgess, W. H., Dickerson, K., Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J. Cell. Biol. 1990, 111, 3155-3164.
21. Godyna, S., Diaz-Ricart, M., Argraves, W. S., Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 1996, 88, 2569-2577.
22. Tran, H., Tanaka, A., Litvinovich, S. V., Medved, L. V. et al., The interaction of fibulin-1 with fibrinogen. A potential role in hemostasis and thrombosis. J. Biol. Chem. 1995, 270, 19458-19464.
23. Pan, T. C., Kluge, M., Zhang, R. Z., Mayer, U. et al., Sequence of extracellular mouse protein BM-90/fibulin and its calcium-dependent binding to other basement-membrane ligands. Eur. J. Biochem. 1993, 215, 733-740.
24. Neiman, M., Hedberg, J. J., Donnes, P. R., Schuppe-Koistinen, I. et al., Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment. J. Proteome. Res. 2011, 10, 4925-4934.
25. Dahl, J. S., Moller, J. E., Videbaek, L., Poulsen, M. K. et al., Plasma fibulin-1 is linked to restrictive filling of the left ventricle and to mortality in patients with aortic valve stenosis. J. Am. Heart Assoc. 2012, 1, e003889.
26. Hansen, M. L., Dahl, J. S., Argraves, W. S., Irmukhamedov A. et al., Aortic valve stenosis and atrial fibrillation influence plasma fibulin-1 levels in patients treated with coronary bypass surgery. Cardiology 2013, 126, 202-206.
27. Kruger, R., Schutte, R., Huisman, H. W., Argraves, W. S. et al., NT-proBNP is associated with fibulin-1 in Africans: the SAfrEIC study. Atherosclerosis 2012, 222, 216-221.
28. Scholze, A., Bladbjerg, E. M., Sidelmann, J. J., Diederichsen, A. C. et al., Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovasc. Diabetol. 2013, 12, 6-12.
29. Argraves, W. S., Tanaka, A, Smith, E. P., Twal, W. O. et al., Fibulin-1 and fibrinogen in human atherosclerotic lesions. Histochem. Cell. Biol. 2009, 132, 559-565.
30. Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F. et al., The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997, 25, 4876-4882.
31. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J. et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389-3402.
32. Godyna, S., Mann, D. M., Argraves, W. S., A quantitative analysis of the incorporation of fibulin-1 into extracellular matrix indicates that fibronectin assembly is required. Matrix Biol. 1995, 14, 467-477.
33. Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C. et al., Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell. Proteomics 2014, 13, 907-917.
34. Greene, L. M., Twal, W. O., Duffy, M. J., McDermott, E. W. et al., Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br. J. Cancer 2003, 88, 871-878.
35. Qing, J., Maher, V. M., Tran, H., Argraves, W. S. et al., Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 1997, 15, 2159-2168.
36. Clinton, G. M., Rougeot, C., Derancourt, J., Roger, P. et al., Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. USA 1996, 93, 316-320.
37. Muriel, J. M., Dong, C., Vogel, B. E., Distinct regions within fibulin-1D modulate interactions with hemicentin. Exp. Cell. Res. 2012, 318, 2543-2547.